PF-Atlas › Drugs › PLN-74809

PLN-74809

Idiopathic Pulmonary Fibrosis · Integrin avb6/b1

Clinical trials
4
Mechanism
Integrin avb6/b1
Development stage
Phase II/III
Evidence level
Level 2 (Phase II/III)
Developer
Pliant Therapeutics / UCSF

Overview

INTEGRIS-IPF trial. Dose-dependent FVC preservation. More targeted than current SOC.

PLN-74809 clinical trials

INTEGRIS-IPF (Phase 2)NCT04072315 (Phase 2)NCT04396756 (Phase 2)NCT06097260 (Phase 2)

Explore related

Treatment profileIntegrin avb6/b1All trialsResearch
Medical disclaimer. This page summarizes research about PLN-74809 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.